Swiss Interpharma in deal with Basel University
Interpharma, which represents Swiss research-based drugmakers, has announced the funding of a chair at the University of Basel in Health Economics, to be based in the Economic Science Faculty. The move was timed to coincide with the industry group's 75th anniversary.
Among the research areas to be prioritized by this collaboration between the private sector and academia, is the evolution of the highly-regulated health care and pharmaceutical markets.
Interpharma also organized a conference to discuss the current state of the pharmaceutical sector and its future. Representatives from local firm Actelion, as well as drug majors Merck Serono, Novartis and Roche presented their perspectives for 2020, including the general conditions they consider necessary for the continued success of drug research and manufacturing in Switzerland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze